Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …

Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …

This study investigated the efficacy and safety of interleukin-6 (IL-6) receptor antagonists
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …

Purpose COVID-19 is characterized by dysregulated immune response, respiratory failure
and a relevant mortality rate among hospitalized patients. Interleukin-6 (IL-6) is involved in …

Objective To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in
COVID-19 patients. Data Sources A systematic review of the MEDLINE and Scopus …

Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …

At present, there are no proven agents for treatment of coronavirus disease (COVID-19). The
available evidence has not allowed guidelines to clearly recommend any drugs outside the …

Abstract Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation,
inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been …

Background We systematically reviewed the literature to answer the following research
questions:(1) Does interleukin 6 (IL-6)(receptor) antagonist therapy reduce mortality in …

Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …